Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
about
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patientsCalcium and phosphate impact cardiovascular risk.A computerized treatment algorithm trial to optimize mineral metabolism in ESRD.Pharmacotherapy of end-stage renal disease.End-stage renal diseaseEffects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients.The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE TrialEffects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.Lipids, blood pressure, kidney - what was new in 2011?Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questionsThe full-length calcium-sensing receptor dampens the calcemic response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone.Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease.Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges.Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers.Mechanisms and treatment of extraosseous calcification in chronic kidney disease.Diseases of the parathyroid gland in chronic kidney disease.Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease.Cinacalcet: will it play a role in reducing cardiovascular events?What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.Pharmacological management of cardiorenal syndromes.Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events.Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial.The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.Vitamin D in chronic kidney disease: is the jury in?Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial.Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients--results of the Austrian cohort of the ECHO study.Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells.Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.Evolve trial.
P2860
Q24187385-9BF5BE0F-8F67-4980-B8E4-411731558EABQ27687570-785BDC16-76EF-46D8-BF7F-20C5084B234BQ30421529-92F67CA1-FC47-48E8-88F7-995414D14BD7Q33531889-10D18FBB-C675-4BDE-8CBB-25DBA81C1A66Q33850437-6EE82E77-918B-4F93-809E-F89320323A28Q35115090-9A206512-D273-4A75-8EE6-CD15B7BCF85EQ35219236-450BB6F0-F7B5-4488-A8DA-74F37AF73A4DQ35576108-2313A4EB-B0E4-42FF-90A3-2C7D8ED232E1Q35576155-491AF15B-0D82-4D68-8034-60A84E02133CQ35658608-07D7DEC7-B1EE-4395-8B72-ABB130B0361DQ35691396-EE39AEFA-0F96-4F1B-ADA3-52AC959252EAQ35983513-7426F3EE-BE56-4013-A952-51A14BCB386CQ36900943-9897D312-220B-47D4-86E6-BD05C5BD3E2FQ37087904-CE9101FA-CD89-4963-B9FD-09805B06EADCQ37228193-3247AF6B-67A6-41AC-8834-4033E956FE6EQ37337334-32880975-1F41-46E7-A2DD-5DB2432F7045Q37738896-9EC45EFE-4462-4FC6-8672-04E9D02F5888Q37807991-BC02F3D7-C69A-4D79-8EB4-48DE57851CD8Q37858461-410D3E1B-ACB1-46E3-96EE-7610629C1F1BQ37871341-41DA192B-FADD-40EA-AEF4-1E59C50A515EQ37902504-E1B8D368-E0D8-47ED-8F87-4CE88BEA3F65Q37912038-0B1B0BF2-D7E2-4D25-A10B-A892F592200FQ37916534-1663EFEC-4664-4F7F-9EE3-D21A9E56ACC3Q37993874-DC4CFF63-3C67-4BFB-8070-4985CFAC051AQ38150052-3B9A9C24-0BBA-4BDE-BF23-000E7A880FDEQ39220825-37F77F95-49D7-4089-829C-D4832B0BC4C7Q39740830-4C2A5D47-2093-4C47-9945-A02A25B7FC58Q39912396-17C7E6BB-3BE4-410A-A90A-DBAE668885F0Q41103027-75520B0F-5F6F-4859-996C-EBBE17E10D13Q41696337-2C3B5161-5C8A-417F-B0F7-367B97FE29C6Q41850703-178C6FDD-49AC-4DBA-8C7B-35335CFB15F7Q42683242-0461F162-8461-4D45-9D73-69711262F379Q43427754-85086DE7-CAA2-4B6F-8937-6F081B9795D4Q43475954-B8079AF0-0682-4153-A15E-3125EBFF70EFQ43692218-C31A085B-2773-49FD-8A75-0DB7D807D438Q43826461-68088CF2-3CC9-4AAE-8CE6-E59CB3F07C5CQ44186583-46FEA99D-96BD-4092-8893-A804D72A5A26Q45002024-F404397A-67C1-45DE-B751-7B765175C5E5Q46305757-F4A7FC7C-3845-4446-A1B4-8F7A30198582Q47095498-9F307841-6CCE-4EC2-8842-0FB4DDF3B739
P2860
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Evaluation of Cinacalcet Thera ...... rationale and design overview.
@en
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events
@nl
type
label
Evaluation of Cinacalcet Thera ...... rationale and design overview.
@en
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events
@nl
prefLabel
Evaluation of Cinacalcet Thera ...... rationale and design overview.
@en
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events
@nl
P2093
P356
P1476
Evaluation of Cinacalcet Thera ...... rationale and design overview.
@en
P2093
David C Wheeler
Geoffrey A Block
Gerard M London
Glenn M Chertow
Jürgen Floege
Kurt Olson
Lara B Pupim
Moetaz Albizem
Patrick Parfrey
Preston Klassen
P304
P356
10.2215/CJN.04381206
P577
2007-08-16T00:00:00Z